VANCOUVER, BRITISH COLUMBIA - Helix BioPharma Corp. (TSX: HBP, OTC PINK: HBPCD, FRANKFURT: HBP0), a clinical-stage oncology company, today announced immediate changes to its Board of Directors. Janusz Grabski has resigned from the Board, and Thomas Mehrling, M.D., Ph.D., who serves as Helix's Chief Executive Officer, has been formally appointed as a director. This appointment aligns with the Board nomination right granted to Laevoroc Immunology AG in connection with Helix's 2025 acquisition of substantially all of the assets of Laevoroc Immunology AG and Laevoroc Chemotherapy AG.
The board changes are intended to ensure that Helix's Board continues to meet its evolving governance and capital markets requirements. The appointments are designed to bring the composition and experience needed to support the Company's clinical development and broader corporate objectives. The Board expressed gratitude to Mr. Grabski for his service and contributions, wishing him success in future endeavors.
Helix BioPharma is a clinical-stage oncology company focused on developing therapies for underserved patient populations with difficult-to-treat cancers. The Company's pipeline is led by L-DOS47, a clinical-stage antibody-enzyme conjugate being developed as a combination therapy for non-small cell lung cancer (NSCLC). Additional pipeline candidates include LEUMUNA™, a pre-IND oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA™, a pre-IND gemcitabine prodrug for advanced solid tumors.
These governance changes come at a pivotal time as Helix advances its clinical programs and seeks to position itself for future growth. The addition of Dr. Mehrling to the Board is expected to strengthen the alignment between management and the Board, facilitating strategic decision-making. Dr. Mehrling's dual role as CEO and director underscores the Board's confidence in his leadership and vision for the Company.
The Company's common shares are listed on the Toronto Stock Exchange (TSX: HBP), quoted on the OTC Pink Market (HBPCD), and listed on the Frankfurt Stock Exchange (FWB: HBP0). For more information about Helix and its pipeline, visit Helix BioPharma's website. Additional details regarding the acquisition from the Laevoroc Group can be found in the company's announcement on this page.
The board changes reflect Helix's commitment to maintaining robust governance as it navigates the complexities of clinical development and capital markets. With a focus on difficult-to-treat cancers, Helix continues to advance its pipeline, and the board's composition is critical to supporting these efforts. The appointment of Dr. Mehrling is a strategic move that aligns leadership with the company's long-term objectives.
